Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
US11266599B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 7, 2020 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Aug 7, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An embodiment of the present invention provides for a dry powder pharmaceutical composition suitable for dispersion in an aerosol for inhaled administration to a patient with cancer, the composition comprising: a cytidine analogue including salts, solvates, hydrates, and esters thereof; and a pharmaceutically acceptable excipient together forming the dry powder pharmaceutical composition suitable for dispersion in the aerosol for administration via inhalation to the patient with cancer. Another embodiment provides for a method of making the composition and a further embodiment provides for a method a treating a patient in need thereof with the composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.